Welcome to the Huntington Project
The Huntington Project brings together clinical and basic scientists, individuals and families affected by Huntington’s disease (HD), advocacy groups, and all others in the HD community to find and develop treatments that make a difference in the lives of those affected by HD. By engaging the entire community in the planning and execution of clinical research, the Huntington Project will maximize the efficiency and fruitfulness of the search.
THE HUNTINGTON PROJECT – BASIC PRINCIPLES
• Inclusion of entire HD community
• Broad-based yet coordinated effort
• Respect for all ideas and contributions
• Cooperative spirit
• Commitment to action
Spring 2009 Features:
HART: A MULTI-CENTER, NORTH AMERICAN, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP STUDY COMPARING THREE DOSES OF ACR 16 VERSUS PLACEBO FOR THE SYMPTOMATIC TREATMENT OF HUNTINGTON DISEASE - THE HART STUDY IS NOW OPEN FOR ENROLLMENT
The HART trial was recently launched. Please see Currently Enrolling, the HART Press Release and Dr. Marsha Miller's February 2009 article and Dr. LaVonne Goodman's February 2009 article for more information. Thank you.
TETRABENAZINE (XENAZINE) UPDATE
Back in August 2008 the U.S. Food and Drug Administration approved tetrabenazine, the first drug approved for use in the United States to treat Huntington’s disease. The action came about eight months after an advisory panel unanimously voted to advise FDA to make the medication available to treat the disease. Tetrabenazine, now known as 'Xenazine', is now available in the United States (read more...).
2CARE: COENZYME Q10 IN HUNTINGTON'S DISEASE - THE 2CARE TRIAL CONTINUES TO ENROLL STUDY PARTICIPANTS
The 2CARE study was launched in March 2008. Please see Currently Enrolling for more 2CARE information, as well as other trials that are enrolling participants.
SET-HD
The Huntington Project SET-HD initiative has collected nominations from researchers, scientists, and community members for compounds that may be useful for clinical study in Huntington's disease. Some of these nominations are reviewed in detail in the SET-HD Compound Review section of this web site.
COHORT UPDATE
The first patient was enrolled in COHORT on February 14, 2006. There are over 1,800 participants enrolled, with more participants joining the study weekly. Thank you Huntington’s community and HSG research sites for all of your efforts to propel the COHORT study forward. 39 participating research sites are currently up and running and able to enroll participants. The remaining site is processing their paperwork and should be accepting participants soon. We are recruiting individuals with HD and individuals from HD families – please see the COHORT Participating Site list for a site near you.
UPCOMING MEETING LINKS
4th Annual CHDI HD Therapeutics Conference, April 27-30, 2009 (read more...)
24th Annual HDSA Convention, June 5-7, 2009 - Registration is Open! (read more...)
World Congress on Huntington's Disease, September 12-15, 2009 - Registration is Open! (read more...)